Literature DB >> 21044428

How does methotrexate suppress inflammation?

B Cronstein1.   

Abstract

Methotrexate remains the most widely used agent for the treatment of rheumatoid arthritis and other chronic inflammatory diseases. Although introduced as a chemotherapeutic agent for the treatment of malignancies, it is clear that, in the doses used, the mechanism of action in the suppression of inflammation differs from simply suppression of purine and pyrimidine metabolism, resulting in inhibition of proliferation. Here we review the proposed mechanisms of action of methotrexate.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21044428

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  18 in total

Review 1.  Adenosine production: a common path for mesenchymal stem-cell and regulatory T-cell-mediated immunosuppression.

Authors:  Martha de Oliveira Bravo; Juliana Lott Carvalho; Felipe Saldanha-Araujo
Journal:  Purinergic Signal       Date:  2016-08-25       Impact factor: 3.765

Review 2.  Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review.

Authors:  Susan M Goodman; Bruce N Cronstein; Vivian P Bykerk
Journal:  Clin Exp Rheumatol       Date:  2014-12-23       Impact factor: 4.473

3.  Intra-silicone oil injection of methotrexate at the end of vitrectomy for advanced proliferative diabetic retinopathy.

Authors:  K Ghasemi Falavarjani; M Modarres; A Hadavandkhani; A Karimi Moghaddam
Journal:  Eye (Lond)       Date:  2015-07-10       Impact factor: 3.775

Review 4.  Mesenchymal stem cell treatments in rheumatology: a glass half full?

Authors:  Alan Tyndall
Journal:  Nat Rev Rheumatol       Date:  2013-11-12       Impact factor: 20.543

Review 5.  Adenosine kinase: exploitation for therapeutic gain.

Authors:  Detlev Boison
Journal:  Pharmacol Rev       Date:  2013-04-16       Impact factor: 25.468

6.  Fibroblasts from methotrexate-sensitive mice accumulate methotrexate polyglutamates but those from methotrexate-resistant mice do not.

Authors:  Xin You; Adrienne Williams; Thierry Dervieux; Wenjie He; Bruce N Cronstein
Journal:  Clin Exp Rheumatol       Date:  2013-03-04       Impact factor: 4.473

7.  Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity.

Authors:  Jonathan L Marks; Christopher J Edwards
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-06       Impact factor: 5.346

8.  A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release.

Authors:  Katia Varani; Melissa Padovan; Fabrizio Vincenzi; Martina Targa; Francesco Trotta; Marcello Govoni; Pier Andrea Borea
Journal:  Arthritis Res Ther       Date:  2011-12-06       Impact factor: 5.156

9.  A(2A) adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats.

Authors:  Fabrizio Vincenzi; Melissa Padovan; Martina Targa; Carmen Corciulo; Sarah Giacuzzo; Stefania Merighi; Stefania Gessi; Marcello Govoni; Pier Andrea Borea; Katia Varani
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

10.  Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs.

Authors:  Bruna Corominas-Faja; Rosa Quirantes-Piné; Cristina Oliveras-Ferraros; Alejandro Vazquez-Martin; Sílvia Cufí; Begoña Martin-Castillo; Vicente Micol; Jorge Joven; Antonio Segura-Carretero; Javier A Menendez
Journal:  Aging (Albany NY)       Date:  2012-07       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.